"NCT00088530". BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). ClinicalTrials.gov. Retrieved 31 January 2012.
"NCT00551239". Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. ClinicalTrials.gov. 31 January 2012. Retrieved 31 January 2012.
"NCT00268853". A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin. ClinicalTrials.gov. Retrieved 31 January 2012.
"NCT00101049". BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). ClinicalTrials.gov. Retrieved 31 January 2012.
doi.org
Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, et al. (2007). "Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone". Invest New Drugs. 25 (3): 187–95. doi:10.1007/s10637-007-9037-8. PMID17285358. S2CID20933712.
Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, et al. (1994). "6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations". J Med Chem. 37 (6): 828–37. doi:10.1021/jm00032a018. PMID8145234.
Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP (1993). "Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II". Biochem. Pharmacol. 46 (2): 265–71. doi:10.1016/0006-2952(93)90413-Q. PMID8394077.
Engert A, Herbrecht R, Santoro A, Zinzani PL, Gorbatchevsky I (September 2006). "EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma". Clin Lymphoma Myeloma. 7 (2): 152–4. doi:10.3816/CLM.2006.n.055. PMID17026830.
Gonsette RE, Dubois B (August 2004). "Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity". J. Neurol. Sci. 223 (1): 81–6. doi:10.1016/j.jns.2004.04.024. PMID15261566. S2CID35170743.
Mazzanti B, Biagioli T, Aldinucci A, Cavaletti G, Cavalletti E, Oggioni N, et al. (November 2005). "Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis". J. Neuroimmunol. 168 (1–2): 111–7. doi:10.1016/j.jneuroim.2005.07.010. PMID16120465. S2CID32913479.
Colombo R, Carotti A, Catto M, Racchi M, Lanni C, Verga L, et al. (April 2009). "CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity". Electrophoresis. 30 (8): 1418–29. doi:10.1002/elps.200800377. PMID19306269. S2CID6594113.
espacenet.com
worldwide.espacenet.com
US patent 5587382, Krapcho AP, Hacker MP, Cavalletti E, Giuliani FC, "6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity", issued 24 December 1996, assigned to Boehringer Mannheim Italia, SpA
EP patent 1503797, Bernareggi A, Livi V, "Injectable Pharmaceutical Compositions of an Anthracenedione Derivative with Anti-Tumoral Activity", published 27 November 2003, issued 2008-09-29, assigned to Cell Therapeutics Europe S.R.L.
europa.eu
ema.europa.eu
"Pixuvri EPAR". European Medicines Agency. 31 May 2012. Retrieved 12 July 2024.
fda.gov
Vesely N, Eckhardt SG (22 March 2010). "NDA 022-481 PIXUVRI (pixantrone dimaleate) injection"(PDF). Summary Minutes of the Oncologic Drugs Advisory Committee. United States Food and Drug Administration. Retrieved 31 January 2012.
Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, et al. (2007). "Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone". Invest New Drugs. 25 (3): 187–95. doi:10.1007/s10637-007-9037-8. PMID17285358. S2CID20933712.
De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, et al. (1995). "Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives". Mol. Pharmacol. 48 (1): 30–8. PMID7623772.
Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, et al. (1994). "6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations". J Med Chem. 37 (6): 828–37. doi:10.1021/jm00032a018. PMID8145234.
Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP (1993). "Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II". Biochem. Pharmacol. 46 (2): 265–71. doi:10.1016/0006-2952(93)90413-Q. PMID8394077.
Engert A, Herbrecht R, Santoro A, Zinzani PL, Gorbatchevsky I (September 2006). "EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma". Clin Lymphoma Myeloma. 7 (2): 152–4. doi:10.3816/CLM.2006.n.055. PMID17026830.
Gonsette RE, Dubois B (August 2004). "Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity". J. Neurol. Sci. 223 (1): 81–6. doi:10.1016/j.jns.2004.04.024. PMID15261566. S2CID35170743.
Mazzanti B, Biagioli T, Aldinucci A, Cavaletti G, Cavalletti E, Oggioni N, et al. (November 2005). "Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis". J. Neuroimmunol. 168 (1–2): 111–7. doi:10.1016/j.jneuroim.2005.07.010. PMID16120465. S2CID32913479.
Colombo R, Carotti A, Catto M, Racchi M, Lanni C, Verga L, et al. (April 2009). "CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity". Electrophoresis. 30 (8): 1418–29. doi:10.1002/elps.200800377. PMID19306269. S2CID6594113.
Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, et al. (2007). "Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone". Invest New Drugs. 25 (3): 187–95. doi:10.1007/s10637-007-9037-8. PMID17285358. S2CID20933712.
Gonsette RE, Dubois B (August 2004). "Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity". J. Neurol. Sci. 223 (1): 81–6. doi:10.1016/j.jns.2004.04.024. PMID15261566. S2CID35170743.
Mazzanti B, Biagioli T, Aldinucci A, Cavaletti G, Cavalletti E, Oggioni N, et al. (November 2005). "Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis". J. Neuroimmunol. 168 (1–2): 111–7. doi:10.1016/j.jneuroim.2005.07.010. PMID16120465. S2CID32913479.
Colombo R, Carotti A, Catto M, Racchi M, Lanni C, Verga L, et al. (April 2009). "CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity". Electrophoresis. 30 (8): 1418–29. doi:10.1002/elps.200800377. PMID19306269. S2CID6594113.